Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?
Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?
复制标题
DOI：
10.1586/1744666x.2015.1054374
复制
发表时间：
2015-07
影响因子：
4.4
通讯作者：
S. Waqar;D. Morgensztern
中科院分区：
文献类型：
--
作者：
S. Waqar;D. Morgensztern
在这篇社论中，我们强调了免疫疗法治疗非小细胞肺癌的令人兴奋的进展，nivolumab是美国FDA批准用于治疗鳞状肺癌的第一个免疫治疗剂，其他几种有前途的免疫检查点抑制剂目前正在临床试验中进行评估。下一步是了解耐药机制并开发合理的组合，以进一步提高肺癌的反应和生存率。
In this editorial, we highlight the exciting advances in immunotherapy for the treatment of non-small cell lung cancer, with nivolumab being the first immunotherapeutic agent to be approved by the US FDA for the treatment of squamous lung cancer and several other promising immune checkpoint inhibitors currently being evaluated in clinical trials. The next step is to understand the mechanisms of resistance and develop rational combinations in an attempt to further improve the responses and survival in lung cancer.